Ozagrel hydrochloride hydrate, >=98% (HPLC), solid

Application

Ozagrel hydrochloride hydrate has been used as a thromboxane synthase inhibitor:in high cholesterol-diet rats (HC) to test its effect on arteriolar constrictionto pre-treat mice to test its effect on lipopolysaccharide (LPS)-induced behavioral changesto test its effect on arteriolar vasoconstriction inhyperglycemic mice

Biochem/physiol Actions

Ozagrel is a selective thromboxane A₂ synthase (TXA₂) inhibitor.

Ozagrel is useful in treating lacunar and thrombotic stroke. It blocks vasoconstriction and platelet aggregation. Ozagrel aids in improving the prostacyclin (PGI2)/ thromboxane A2 (TXA2)in the acute phase of cerebral ischemia. It improves endothelial dysfunction in L-methionine-induced hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID).

Packaging

5, 25 mg in glass bottle